Table 2.

Correlation between clinicopathologic findings and the prevalence of TR

CharacteristicsRatio of TR in CD4+ T cellsP
Low TRHigh TR
Age (y)
    ≥6043 (41.3)39 (41.5)
    <6061 (58.7)55 (58.5)0.98
Sex
    Male62 (59.6)52 (55.3)
    Female42 (40.4)42 (44.7)0.54
Pathologic tumor status
    pT17 (6.7)5 (5.3)
    pT216 (15.4)10 (10.6)
    pT356 (53.8)45 (47.9)
    pT425 (24.0)34 (36.2)0.29
Pathologic node status
    pN022 (21.2)12 (12.8)
    pN1a21 (20.2)15 (16.0)
    pN1b61 (58.7)67 (71.3)0.16
Pathologic metastasis status
    pM079 (76.0)53 (56.4)
    pM125 (24.0)41 (43.6)0.0035*
Stage
    I9 (8.7)7 (7.4)
    II8 (7.7)2 (2.1)
    III45 (43.3)29 (30.9)
    IVA17 (16.3)15 (16.0)
    IVB25 (24.0)41 (43.6)0.029*
Tumor grade
    121 (21.4)3 (3.3)
    271 (72.4)69 (76.7)
    36 (6.1)18 (20.0)0.0002*
Tumor margin status
    Negative70 (67.3)61 (64.9)
    Positive34 (32.7)33 (35.1)0.72
Lymphatic invasion
    Negative8 (7.7)5 (5.3)
    Positive96 (92.3)89 (94.7)0.5
Vascular invasion
    Negative13 (12.5)8 (8.5)
    Positive91 (87.5)86 (91.5)0.36
Perineural invasion
    Negative4 (3.8)7 (7.4)
    Positive100 (96.2)87 (91.5)0.27
  • * Significant.

  • Tumors of special types of histology (adenosquamous cell carcinoma, etc.) are avoided.

  • Classified according to the classification of pancreatic carcinoma of Japan Pancreas Society.